Centessa Pharmaceuticals plc

NASDAQ:CNTA

Biotechnology

Healthcare
$40.50 -0.19%

-$0.07 today

Market cap
$6.27B
Beta
1.12
P/E (TTM)
-24.4
EPS (TTM)
-$1.63
52W Low $12.30High $40.26

Volume 0.00M

Average 2.63M

CNTA Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Centessa Pharmaceuticals plcNASDAQ: CNTA

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -$238.6K, compared with $15M a year earlier. Trailing-twelve-month gross profit was -$238.6K.

Context

  • Gross profit amounted to 100.0% of revenue in FY2025.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$238.6K or moves back toward the trailing-twelve-month quarterly average of -$59.65K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$238.6K— QoQ
Last fiscal yearDec 2025
$15M— YoY
LTMMar 2026
-$238.6K-101.6% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-101.6%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
15M USD
Year-over-year change
—

Gross Profit vs competitors

How CNTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -101.6% is the lowest of 8, against a peer median of +11.3%.
CNTA Competitors
Gross Profit for CNTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$774.12M USD+40.6%+129.1%57.0%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$559.44M USD+11.3%+19.0%83.6%
AAPGAscentage Pharma Group InternationalFY2025CN¥426.75M CNY-55.2%+31.5%76.4%
ZLABZai Lab LimitedLTM Jun 2026$253.9M USD-4.9%+24.0%56.5%
CELCCelcuity Inc.LTM Jun 2026-$47K USD-33.3%——
CNTACentessa Pharmaceuticals plcLTM Mar 2026-$238.6K USD-101.6%——
APGEApogee Therapeutics, Inc.LTM Jun 2026-$408K USD———
DYNDyne Therapeutics, Inc.LTM Jun 2026-$521K USD———
XENEXenon Pharmaceuticals Inc.LTM Sep 2026-$611K USD+99.1%-19.3%—
CGONCG Oncology, Inc. Common stockLTM Sep 2026-$6.3M USD+92.6%—102.2%
Peer median (excluding CNTA) —+11.3%+24.0%76.4%

Competitors are the stored peer set for CNTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue006.85M015M
Cost of Revenue00000
Gross Profit006.85M015M
Gross Margin——100.0%—100.0%
Research & Development96.32M155.08M124.41M150.24M172.22M
Selling, General & Admin43.01M55.2M53.73M50.81M50.47M
Operating Expenses374.87M212.26M178.14M201.06M222.69M
Depreciation & Amortization34K131K810K942K921K
EBITDA(139.3M)(209.55M)(165.43M)(221.88M)(183.33M)
EBITDA Margin——-2413.9%—-1222.2%
Operating Income(374.87M)(212.26M)(171.28M)(201.06M)(207.69M)
Operating Margin——-2499.4%—-1384.6%
Interest Income0244K10.48M14.02M20.53M
Interest Expense2.55M7.28M9.91M10.09M11.46M
Other Income / Expenses(6.92M)(4.69M)(4.86M)(31.86M)11.98M
Income Before Tax(381.79M)(216.95M)(176.14M)(232.91M)(195.71M)
Pre-Tax Margin——-2570.3%—-1304.8%
Income Tax Expense114K(747K)(25.06M)2.84M1.82M
Net Income(381.9M)(216.21M)(151.09M)(235.76M)(197.53M)
Net Margin——-2204.7%—-1316.9%
EPS (Basic)(4.24)(2.31)(1.57)(2.06)(1.46)
EPS (Diluted)(4.24)(2.31)(1.57)(2.06)(1.46)
Weighted Avg Shares89.99M93.4M96.18M114.47M135.72M
Weighted Avg Shares (Diluted)89.99M93.4M96.18M114.47M135.72M

Centessa Pharmaceuticals plc

NASDAQ:CNTA

Intrinsic Alpha fair value

Locked

Current Price

$40.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.